FDA Accepts Supplement for ADEMPAS (NDA204819) from Bayer Healthcare
The FDA has accepted a supplemental application for ADEMPAS (NDA204819) from Bayer Healthcare.
Company
Pharmaceutical intelligence for Bayer with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.